<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Flip News — gilead news</title>
    <link>https://flipnews.co.uk/topics/gilead/</link>
    <description>The latest Flip News stories on gilead.</description>
    <language>en-GB</language>
    <lastBuildDate>Sun, 04 Oct 2026 15:36:47 GMT</lastBuildDate>
    <atom:link href="https://flipnews.co.uk/topics/gilead/feed.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Over 250 join trial of Gilead's obeldesivir as Ebola prevention pill in Congo</title>
      <link>https://flipnews.co.uk/health/ebola-obeldesivir-pep-trial/</link>
      <guid isPermaLink="true">https://flipnews.co.uk/health/ebola-obeldesivir-pep-trial/</guid>
      <pubDate>Sun, 04 Oct 2026 00:00:00 GMT</pubDate>
      <description>More than 250 people have enrolled in the EBO-PEP trial in the Democratic Republic of the Congo testing Gilead's experimental antiviral obeldesivir as post-exposure prophylaxis against the Bundibugyo virus behind the country's deadliest Ebola outbreak.</description>
      <author>Priya Raman</author>
      <category>ebola-outbreak</category>
      <category>drc</category>
      <category>clinical-trials</category>
      <category>gilead</category>
      <source url="https://www.arabnews.pk/world/inside-the-study-for-a-remedy-to-fight-congos-deadliest-ebola-outbreak-3003085">Associated Press</source>
    </item>
  </channel>
</rss>
